Publications by authors named "P LoRusso"

Claim this Profile
F
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials.
Stacy S Shord, Cong Chen, Jin Y Jin, Scott Van Wart, Sarah K Martin, Patricia M LoRusso

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers.
Olanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci, Alexia Iasonos, Brad A Davidson, Patricia M LoRusso

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Dosages for First-in-Human Trials.
Hao Zhu, Alex N Phipps, Ying Yuan, Brad A Davidson, Stacy S Shord, Patricia M LoRusso

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer.
D Yee, H Iwata, P LoRusso, M Oliveira, A Gonçalves

ESMO Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties.
Janie Yue Zhang, Barani Kumar Rajendran, Shruti S Desai, Joanna Gibson, Jassim DiPalermo, Patricia LoRusso

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis